You are now leaving the LillyMedical website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.

Welcome to the Lilly Scientific Information Page for ATTD 2026

Advanced Technologies & Treatments for Diabetes

Barcelona, Spain

March 11, 2026 - March 14, 2026

Quicklinks

Investigator Initiated Research

See how Lilly supports external requests for provision of study drug and/or financial support

To stay informed on the latest science and innovation, please be sure to follow us on Twitter/X

To stay informed on the latest science and innovation from Lilly Medical, please be sure to follow us on LinkedIn

Disclosures

THURSDAY

MARCH 12, 2026, 5:40 p.m. CET

Disease State: Diabetes Mellitus
Presented by: Natalie Bellini
Molecule(s): Insulin Efsitora Alfa

Duration of Hypoglycaemia With Once-Weekly Insulin Efsitora Alfa Versus Once-Daily Basal Insulins in Adults With Type 2 Diabetes: Exploratory Analysis of QWINT 2–4

Trial(s) Overview:

THURSDAY

MARCH 12, 2026, 5:30 p.m. CET

Disease State: Diabetes Mellitus
Presented by: Tim Heise
Molecule(s): Insulin Efsitora Alfa

Steady-State Pharmacokinetics and Glucodynamics of Once-Weekly Insulin Efsitora Alfa (Efsitora) in Individuals With Type 2 Diabetes (T2D)

Trial(s) Overview:

NCT06169982

Presentation

THURSDAY

MARCH 12, 2026, 5:50 p.m. CET

Disease State: Diabetes Mellitus
Presented by: Yuxin Yang
Molecule(s): Insulin Efsitora Alfa

Efficacy and Safety of Once-Weekly Basal Insulin Efsitora Compared With Insulin Degludec in Insulin-Naïve East Asian Adults With Type 2 Diabetes

Trial(s) Overview:

QWINT-2

Presentation

THURSDAY

MARCH 12, 2026, 6:00 p.m. CET

Disease State: Diabetes Mellitus
Presented by: Thomas Martens
Molecule(s): Insulin Efsitora Alfa

Use of CGM Indicators to Guide Dose Titration of Weekly Basal Insulin in T2D

Trial(s) Overview:

BDCT

Presentation

THURSDAY

MARCH 12, 2026, 8:30 a.m. CET

Disease State: Diabetes Mellitus
Presented by: Stefano Del Prato
Molecule(s): Tirzepatide

Efficacy and Safety of Tirzepatide Compared With Intensified Conventional Care in Adults Initiating Treatment Early in the Course of Type 2 Diabetes: Results from SURPASS-EARLY Study after 2 Years of Treatment

Trial(s) Overview:

SURPASS-EARLY

Presentation